Oramed Pharmaceuticals Inc. announced that the United States Patent and Trademark Office has granted the Company a patent titled "Methods and Compositions for Treating Diabetes." The patent serves as an extension to a patent previously granted in May 2022 and addresses methods and compositions for treating diabetes mellitus through oral pharmaceutical compositions comprising insulin in combination with Glucagon-like Peptide 1 (GLP-1).
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.08 USD | -2.35% | -3.24% | -9.52% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.52% | 86.54M | |
+48.95% | 56.95B | |
+39.98% | 40.26B | |
-7.10% | 39.32B | |
-4.42% | 28.37B | |
+12.47% | 26.45B | |
-18.47% | 19.41B | |
+29.39% | 12.54B | |
+25.80% | 12.21B | |
-0.14% | 12.15B |
- Stock Market
- Equities
- ORMP Stock
- News Oramed Pharmaceuticals Inc.
- Oramed Pharmaceuticals Inc. Granted U.S. Combination Therapy Patent for Oral Glp-1 & Insulin for the Treatment of Diabetes